logo
Share SHARE
FONT-SIZE Plus   Neg

AstraZeneca Plans To Conduct New Study Of BRILINTA In PAD Patients

AstraZeneca Plc (AZN,AZN.L) unveiled plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease, or PAD, a condition affecting approximately 27 million people in Europe and North America. PAD patients are at high risk of myocardial infarction, strokes, and other health complications.

EUCLID is designed to evaluate cardiovascular event rate and safety in PAD patients. BRILINTA (Ticagrelor) is currently not approved for the treatment of patients with PAD.

EUCLID is a randomized, double-blind, parallel group, multi-center study evaluating the efficacy of ticagrelor (monotherapy) compared to clopidogrel (monotherapy) in reducing the primary endpoint - a composite of cardiovascular death, myocardial infarction or ischemic stroke - in patients with PAD.

In the EUCLID study, symptomatic PAD patients who are 50 years of age or older will be randomized to receive either ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily. Now that plans to initiate the study have been finalized, the EUCLID steering committee will begin the process of recruiting study investigators, clinical centers, and eventually patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sobeys Inc. is cutting 800 jobs across Canada as part of the grocery store chain's efforts to cut costs and streamline its organization. Sobeys is Canada's second-largest grocery chain behind Loblaw Companies Ltd. The job cuts come as Sobeys, like others in the industry, grapple with stiff competition from rivals, higher costs and technological change. This year's holiday shopping season has got off to a strong start. Online shoppers spent $1.52 billion on Thanksgiving Day, with smartphones accounting for 46 percent of all traffic to U.S. retail websites, according to Adobe Analytics data. The $1.52 billion in online spend by Thanksgiving evening represents 16.8 percent growth from last year, according to the data. Shares of thyssenKrupp AG were gaining around 2 percent in the morning trading in Germany after the steel giant Thursday said it expects clearly positive net income and significantly higher adjusted EBIT, a key earnings metric, in fiscal 2018. This was after reporting higher adjusted EBIT, sales and order intake in its fiscal 2017, despite a net loss due to charges.
comments powered by Disqus
Follow RTT